A new review of research into the use of probiotics in irritable bowel syndrome finds that only one has been studied sufficiently to be proven effective.
Researchers from the University of Michigan, USA, conducted an analysis of randomized controlled trials evaluating probiotics in the treatment of irritable bowel syndrome (IBS).
Their review, concluded that the only probiotic currently able to demonstrate significant improvement in IBS symptoms based upon a properly designed research study was Bifantis® (Bifidobacterium infantis 35624). This probiotic bacteria is the sole ingredient in Align® which is manufactured by Procter & Gamble.
The goal of the review was to evaluate the efficacy, safety and tolerability of probiotics in the treatment of IBS. Criteria for the study included randomized controlled trials testing adults with IBS symptoms using single or combination probiotics versus placebo for IBS symptoms and frequency of adverse events.